Fig. 10.

SD0006 protects against inflammation-mediated joint and bone destruction. Rats were inoculated with SCW and were either left untreated, or were orally given SD0006 b.i.d. 10 days later. Assessment was conducted on day 21. a Computed tomographies of paws from SCW-treated rats with 15 mg/kg SD0006 b.i.d. (center) and without (top), as compared to a normal, untreated control paw (bottom). Purple represents soft issue that swells with SCW-induced edema. White represents high-density bone, yellow and red are indicative of decreasing bone density and erosion. b Hind paws from rats treated as indicated with SD0006 (4 per group) were analyzed for bone density as described in Material and Methods. Error bars are SEM. Dunnett‘s t test was utilized to compare the normal control with the drug-dosed groups following a one-way ANOVA overall significant F test of the bone density data. The 7.9- and 25-mg/kg b.i.d. SD0006 dose groups and the dexamethasone (Dex)-treated group were all shown to be statistically indistinguishable from the normal control with p values ≥ 0.994 for the comparisons.